Catalyst Brief

← Calendar

Readoutin 14d

Karyopharm Therapeutics Inc — Selinexor (combination therapy)

Phase 3 primary completion: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Date
Dec 2026
Type
Readout
Indication
Relapsed/Refractory Diffuse Large B-cell Lymphoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.